블로그
-
Just Like Baldur's Gate 3, Larian Hopes It Can Give Divinity The Early Access Treatment
1 Just Like Baldur's Gate 3, Larian Hopes It Can Give Divinity The Early Access Treatment Games launching decade so far, enjoyed huge success following its early access period, so it makes sense that Larian is
blog.naver.com · 2025.12.18
-
[유진성형외과] 붓기줄이는 생활루틴 best5
⠀ 문의 및 상담 전화: 1577-1711 카톡: @유진성형외과 카카오톡 채널: 유진성형외과 위치: 서울시 강남구 역삼동 827-66 ⠀ ⠀ Post-treatment swelling is completely normal, but with the right daily routines, you can speed up the healing process✨ ⠀ In
blog.naver.com · 2025.12.02
-
Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer
mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer Abstract Among women, breast cancer is This is a specific treatment that stops the growth of cancer cells.......
blog.naver.com · 2025.11.02
-
[유진성형외과] 리프팅 시술 고민하시는 분들에게 울쎄라 vs 써마지
If you’re considering a lifting treatment, this is a must-know comparison!
blog.naver.com · 2025.10.03
-
답십리 미용실 추천!! 손상모 복구 매직 잘하는 고아라 헤어케어 by 고아라 원장님
from frequent coloring, perms, or heat styling can be revived through our premium hair repair magic treatment Our specialized magic straightening for damaged hair is highly recommended.......
blog.naver.com · 2025.09.10
-
강남역 미용실 추천! 탈색 없이 완성하는 레드 브라운 컬러 톤 보정 염색 고아라헤어케어 희선 원장님
Hair that was damaged and faded by the summer sun is transformed into a smoother, more polished tone after the treatment.
blog.naver.com · 2025.09.05
-
Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer...
breast cancer models Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment However, their long-term efficacy is limited by acquired resistance, and CDK4/6i monotherapy remains
blog.naver.com · 2025.08.15
-
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer
after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Background Breast cancer is /HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy.
blog.naver.com · 2025.07.08
-
A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab
Background: Adrixetinib (Q702) is an orally administrated novel Axl/Mer/CSF1R tyrosine kinase inhibitor for which the primary mechanism of action of tumor regression is through immune-stimulating effects.
blog.naver.com · 2025.06.03
-
[] Precipitation Hardening (PH) Stainless Steels
The principle of precipitation hardening is that a supercooled solid solution (solution annealed) changes hardened (strengthened) by treatment at 900-1100°F, minimizing the problems associated with .......
blog.naver.com · 2025.05.27
